T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, and immune monitoring products and services, launched CFSE T cell proliferation assays for immunogenicity risk assessment. The assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage. Combined with ProImmune’s unique cell-free HLA-peptide binding assays for more than 50 class II HLA

Trevigen offers a validated assay with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening. In cancer drug development, a current molecular target of high interest is poly (ADP-ribose) polymerase (PARP), which is involved in DNA repair and the survival or death of cancer cells. Measuring the effectiveness of PARP inhibitors in cell and tissue lysates has been difficult and

Proximagen Neuroscience plc, a biotechnology company focused on diseases of the central nervous system, announces that it has signed a development, license and sub-license agreement with Upsher-Smith Laboratories Inc. in relation to tonabersat, a drug compound recently acquired by Proximagen through its acquisition of Minster Pharmaceuticals plc. Under the terms of the agreement, Upsher-Smith will undertake the clinical development, regulatory filing, and commercialization of